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Among the issues dealing with identifying potential adverse immunologic effects (i.e., suppression,
hypersensitivity, or autoimmunity) associated with xenobiotic exposure, general agreement exists
among the regulatory and pharmaceutical communities that predictive tests for autoimmunity are in
most need of development in order to improve risk assessment. The estimation of risk (i.e., the
probability of a deleterious effect resulting from exposure) involves both the qualitative evaluation of
whether a hazard exists and the quantitative evaluation for determining an acceptable level of
exposure in humans. Unless adequate human data are available, which is uncommon, this is based
on animal studies. Although animal models exist to study autoimmune processes, these models do
not readily lend themselves to interpretation in the risk assessment process due, for the most part,
to the complexity of autoimmune disease(s), as they are multifactorial and exhibit genetic
heterogeneity in humans. To improve the risk assessment process, researchers must develop and
validate animal models that not only incorporate mechanistic information into the assessment
process but also allow for consideration of potent genetic, physiologic, and environmental
influences. Key words: autoimmunity tests, immunotoxicology evaluation, immunotoxicology
methods, risk assessment, xenobiotic-induced autoimmunity. - Environ Health Perspect 107(suppl
5):679-680 (1999).
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Overview
A study recently conducted by the
Environmental Defense Fund (1) indicates
that although the number ofchemicals tested
for immunotoxicity is somewhat less than that
for other organ systems, such as the reproduc-
tive, developmental, or nervous systems,
almost 20% ofchemicals present at significant
levels in the environment have been examined
at some level for immunologic effects. A
review ofthe literature, however, indicated the
majority of those chemicals studied were
examined for their ability to cause either
hypersensitivity or immunosuppression, and
only a relatively few were tested for their
potential to produce autoimmunity (2).
These observations appear at odds with results
from a recent survey of the pharmaceutical
industry (3). This survey, inwhich 12 compa-
nies responded, suggested that hematologic or
dermatologic problems consistent with auto-
immunity (or systemic allergy) were the most
common preclinical or postlaunch immuno-
logic observations. Furthermore, the survey
respondents indicated the most immediate
need in the area ofimmunotoxicology evalua-
tion was the development ofpredictive tests
for autoimmunity. Epidemiologic data sup-
port the survey results; approximately 5% of
the U.S. population suffers from some form of
autoimmune disease (4), and 5-20% of
patients receiving certain drugs such as pro-
cainamide orhydralazine develop drug-induced
autoimmune diseases (5).
The question then arises, Why is there a
lack ofvalidated autoimmune models suitable
for drug or chemical screening? Certainly a
large number ofexperimental models are used
successfully to study organ-specific and sys-
temic autoimmunity (Table 1). Furthermore,
although many questions still remain on the
etiology and biology ofautoimmune diseases,
scientists have provided a good road map of
disease development, allowing for successful
application ofnovel biotech therapies such as
cytokine antagonists. The primary reason for
the lackofvalidated screening assays probably
stems from the complexity of the disease.
First, autoimmune disease is not one disease
but a group ofover 30 diseases affecting dif-
ferent organs, often through different mecha-
nisms. Unless a common early process is
identified, a single test would be unlikely to
provide an adequate degree ofconcordance to
be useful for predictive risk assessment.
Second, although most diseases are governed
by genetics, the degree ofgenetic and epige-
netic influences in autoimmune diseases is
such that it could drastically alter the out-
come ofa test. For example, the relative risk
for developing autoimmunity from gold salt
increases 32-fold in individuals who possess
the HL-A DR3 allele (7). Experimental
studies ofmercury-induced autoimmunity in
the Brown-Norway rat and B.10 mouse sug-
gest the same genetic influences apply in ani-
mal models (7). Third, development of
autoimmune disease may occur through one
ofseveral mechanisms, thus increasing the
need to conduct multiple tests in risk assess-
ment. For example, at the cellular level,
autoimmune disease can occur from either
aberrant B-cell or T-cell responses. Thus, ifa
specific autoimmune disease results from a
defect in T cells, assays designed to detect a
defect in B cells would provide a false nega-
tive. At the molecular level, depending upon
the xenobiotic, an autoimmune disease can
develop from the expression (unmasking) of
cryptic determinants, altered immunoregula-
tion such as defects in the expression ofinter-
leukin 4 or interferon-y, or defects in the
establishment of tolerance, which often
involve missed deletion or activation of
autoreactive T cells. Finally, when using ani-
mal models, there is some uncertainty regard-
ing what actually constitutes autoimmunity.
This is reflected in humans by a lack ofwell-
defined diagnostic tests for identifying
autoimmune disease and is discussed in detail
in other articles in this monograph.
Despite these challenges, attempts to
develop predictive screening assays for
detecting xenobiotic-induced autoimmunity
have proceeded in several institutions includ-
ing Virginia Commonwealth University
(Richmond, Virginia) under the National
Toxicology Program, the University of
Utrecht (Utrecht, The Netherlands) funded
by the Dutch Organization for Scientific
Research, and the University of Dusseldorf
(Dusseldorf, Germany). Models proposed to
evaluate the potential of xenobiotics to
induce autoimmunity are
* Popliteal lymph node assay with reporter
antigens
* Increased titers ofautoantibodies
* Examination ofimmunoglobulin
complexes/deposits (immunohistology)
* Spontaneous animal models.
These models are clearly different from
those described in Table 1, as the latter are
designed to investigate the mechanisms of
a specific autoimmune disease. Ofthe four
assays listed, immunohistology, in which
immunoglobulin deposits or complexes are
evaluated either on suspect organs or in the
periphery, has been evaluated the least, whereas
the popliteal lymph node assay with reporter
antigens has been studied the most (8). Details
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Table 1. Examples of experimental models used to
study autoimmune diseases.a
Organ-specific autoimmunity
Induced by immunization (EAE, AA)
Spontaneous mice (NOD,btransgenics)
Toxicant-induced (streptozotocin, Cd)
Systemic autoimmunity
Allogeneic reactions
Neonatal thymectomy
Spontaneous mice (NewZealand mixed)c
Abbreviations: AA, autoimmune arthritis; EAE, experimental
autoimmune encephalitis; NOD, nonobese diabetic. 'Adapted
from Pelletier et al. 16). bDevelop immune diabetes. CProne to
develop systemic lupus erythematosus.
ofthese methods and the results so farobtained
have been discussed by Pieters and Albers (9).
However, none ofthese models have under-
gone a vigorous validation process to provide
sufficient confidence for use in risk assessment.
Such a validation process would involve, at the
minimum, establishing an acceptable level of
concordance and an inter/intralaboratory vali-
dation exercise. The former would involve
determining the assay's sensitivity and speci-
ficity using agents known to induce auto-
immune disease in humans. The inter/
intralaboratory validation component is some-
what less defined but would examine assay
reproducibility, feasibility, accuracy, and in cer-
tain instances, costeffectiveness.
Data used in risk assessment are derived
primarily from animal toxicology studies.
When available, findings from epidemiologic
and controlled clinical exposure studies take
precedent. Results obtained from in vitro
studies, structure-activity relationships, (SARs),
or mechanistic investigations are normally used
only in a supporting role. Mechanistic studies
are particularly helpful, however, as without
them all defaults in the risk assessment process
are assumed valid (e.g., threshold, animal vs
human sensitivity, interindividual variability).
Epidemiologic data represent the "gold stan-
dard" in risk assessment. Epidemiologic studies
involving autoimmune diseases would be com-
plicated by the likelihood that the disease inci-
dence in the exposed population would be
relatively low because ofthe multifactorial and
poly-genetic nature ofthe disease. This would
be further confounded by difficulties in clinical
diagnosis because of a lack ofdefined end
points available. Some ofthese problems would
be circumvented in controlled clinical studies.
However, such studies may be limited with
Table 2. Structure-activity relationships of potential interest.
Activity Chemical example
Estrogenic Diethylstilbestrol
Thymolytic Cyclosporin A,
cyclophosphamide
Formation of protein adducts Halothane
Altered immune regulation Mercury, interferon-y
Myeloperoxidase substrates Procainamide
Altered methylation Hydralazine
respect to the size ofthe population and the
length of treatment and could only be
conducted withpharmaceuticals.
Despite the challenges in developing
appropriate tests for autoimmunity that can
be used in risk assessment, the considerable
amount ofdata generated by immunologists
and pharmacologists pertaining to basic mech-
anisms ofchemical-induced autoimmune dis-
eases have provided a conceptual framework
that allows the establishment of potential
SARs (Table 2) (6, 10). These SARs are by no
means definitive. As the database increases, no
doubt some will not be supported and others
will be added. In all cases these relationships
are supported by basic understanding of
immunologic and pharmacologic processes.
For example, estrogens are known to be a
major factor in classic autoimmune diseases,
presumably because oftheir ability to stimu-
late certain components ofthe immune sys-
tem (11). Laboratory studies have shown that
thymolytic chemicals can induce autoimmu-
nity when given neonatally by altering normal
patterns of autoreactive T-cell deletion, a
process that occurs in the thymus early in life
(12). Chemicals that form protein adducts or
damage tissue in such a way to allow expres-
sion ofcryptic determinants would provide
novel host antigens that could be recognized
by T cells. Agents that have adjuvant activity
or biologicals that stimulate certain cytokines
may shift the balance of T-helper 1 and
T-helper 2 cells and allow exacerbation of
preexisting autoimmune disease (13).
Common features associated with many
drugs that induce autoimmune diseases are
that they serve as myeloperoxidase substrates
and/or cause changes in methylation. The
underlying biology for the latter associations
are less clear but may involve formation of
the specific antigenic epitopes responsible for
the autoimmune response. With regard to the
association with myeloperoxidase substrates,
it has been suggested that many ofthe chemi-
cals require metabolism in proximity to
immune cells in order to be antigenic;
immune cells such as monocytes contain high
levels ofmyeloperoxidase (14).
In any case, based upon the need to
develop predictive screening models to iden-
tify the potential ofxenobiotics to induce or
exacerbate autoimmunity, combined with our
increased understanding of immune and
pharmacologic mechanisms and the rapidly
increasing array of available animal disease
models, suitable tests should be forthcoming.
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